SCHEMBL2953497

SCHEMBL2953497

N=C(NN)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
KDM4E B2RXH2 2/20 0.56
MAPT P10636 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ALDH1A1 P00352 2/20 0.56
MAOB P27338 3/20 0.45
MAOA P21397 2/20 0.45
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
TSHR P16473 3/20 0.41
ALOX15 P16050 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CYP1A2 P05177 1/20 0.38
NFKB1 P19838 1/20 0.38
CYP2A6 P11509 1/20 0.38
IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2849627 0.87 MPO (0.39) LMNAKDM4EMAPTL3MBTL1ALDH1A1
SCHEMBL13108737 0.80 WDR5 (0.44) LMNAKDM4EMAPTL3MBTL1ALDH1A1
SCHEMBL641475 0.78 LMNA (0.50) LMNAKDM4EMAPTL3MBTL1ALDH1A1
SCHEMBL11839172 0.78 PLAU (0.54) LMNAKDM4EMAPTALDH1A1TSHR
SCHEMBL2945608 0.78 LMNA (0.54) LMNAKDM4EMAPTALDH1A1TSHR
SCHEMBL2950699 0.76 ALDH1A1 (0.43) LMNAKDM4EMAPTALDH1A1CES2
SCHEMBL2949849 0.76 MAOA (0.45) ALDH1A1MAOBMAOACES2CES1
SCHEMBL3303670 0.76 IDO1 (0.42) LMNAKDM4EMAPTL3MBTL1ALDH1A1
SCHEMBL12855290 0.76 LMNA (0.48) LMNAKDM4EMAPTL3MBTL1ALDH1A1
SCHEMBL11852572 0.76 IDO1 (0.42) LMNAKDM4EMAPTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070065443-A1 Fructoseamine 3 kinase and the formation of collagen and elastin DYNAMIS THERAPEUTICS, INC. 2007-03-22 US claimed
EP-1753861-A2 FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN Dynamis Therapeutics, Inc. (US) 2007-02-21 EP claimed
WO-2005079463-A2 FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN DYNAMIS THERAPEUTICS, INC. (US) 2005-09-01 WO claimed
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) DYNAMIS THERAPEUTICS, INC. 2005-07-21 US claimed
US-20030219440-A1 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. 2003-11-27 US claimed
WO-2021150700-A1 N-SUBSTITUTED-3-TRICYCLYL PIPERIDINE DERIVATIVES AS ANTICANCER AND NEUROPROTECTIVE AGENTS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-07-29 WO disclosed
US-20100310482-A1 3-Deoxyglucosone And Skin DYNAMIS THERAPEUTICS, INC. (US) 2010-12-09 US disclosed
US-7749503-B2 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. (US) 2010-07-06 US disclosed
US-7671019-B2 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) DYNAMIS THERAPEUTICS, INC. (US) 2010-03-02 US disclosed
US-7622117-B2 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
EP-1576093-A4 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS INC (US) 2009-07-08 EP disclosed
US-20080292568-A1 3-Deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. (US) 2008-11-27 US disclosed
US-6191289-B1 REACTING A 4-OXO-4H-BENZOPYRAN GROUP SUBSTITUTED WITH AMIDE OR A PHENYL GROUP IN ITS 2 POSITION IS REACTED WITH ANHYDROUS HYDRAZINE OR SALT IN PRESENCE OF CATALYST FOLLOWED BY REACTING WITH NITROUS ACID OR SALT TO FORM TETRAZOLE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-02-20 US disclosed
US-5874593-A SULFUR CONTAINING AMIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-02-23 US disclosed
EP-0711762-A1 PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1996-05-15 EP disclosed
US-5262152-A Aging resistance, inhibiting glycosylation of proteins THE ROCKEFELLER UNIVERSITY (US) 1993-11-16 US disclosed
US-5130337-A Aging of proteins by reaction with glucose or other reducing sugar THE ROCKEFELLER UNIVERSITY (US) 1992-07-14 US disclosed
EP-0210291-A1 Platinum complexes of antitumor agents AMERICAN CYANAMID COMPANY (US) 1987-02-04 EP disclosed
US-4544759-A Platinum complexes of antitumor agents AMERICAN CYANAMID COMPANY (US) 1985-10-01 US disclosed
US-3962240-A PROCESS FOR THE PREPARATION OF FURO(3,4-E)-AS-TRIAZINES SANDOZ, INC. (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070065443-A1 Fructoseamine 3 kinase and the formation of collagen and elastin FN3K, PDXK, COLGALT1 LMNA 1512/4885KDM4E 1956/4885MAPT 677/4885
US-20100310482-A1 3-Deoxyglucosone And Skin DPM1, G6PD, UGGT1 LMNA 2324/4885KDM4E 897/4885MAPT 3453/4885
US-20080292568-A1 3-Deoxyglucosone and skin DPM1, G6PD, UGGT1 LMNA 2324/4885KDM4E 897/4885MAPT 3453/4885
US-20030219440-A1 3-deoxyglucosone and skin DPM1, G6PD, UGGT1 LMNA 2324/4885KDM4E 897/4885MAPT 3453/4885
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) AGER, GLA, GALE LMNA 1248/4885KDM4E 441/4885MAPT 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.